Antibody-drug conjugate's biopharmaceutical commercial breakthrough — the commercial success of Kadcyla (ado-trastuzumab emtansine), Enhertu (trastuzumab deruxtecan), Besylomab, and the increasingly crowded FDA-approved ADC commercial landscape demonstrating that the chemical technology of covalently linking cytotoxic drugs to tumor-targeting antibodies creates a commercial therapeutic...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china